Hong Kong-based firm OrbusNeich has reported positive results from the REDUCE trial of its dual therapy stent, Combo, in patients with acute coronary syndrome (ACS).

The results compare the efficacy of the stent at a short-term period of three months with 12-month dual antiplatelet therapy (DAPT).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Combo is designed to repair vessel injury and regenerate endothelium to aid in the natural healing of vessels by enhancing endothelial coverage and control of neointimal proliferation.

The dual therapy stent combines the firm’s endothelial progenitor cell (EPC) capture technology with the delivery of a sirolimus drug elution from a bioresorbable polymer that degrades in 90 days.

As per the data, the stent demonstrated non-inferiority with no difference in the primary endpoint between three and 12 months DAPT in the intent to treat (ITT) population.

Based on the CURE trial performed 20 years ago, current guidelines require continuation of a DAPT therapy using a first-generation drug-eluting stent (DES) for 12 months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“REDUCE showed 8.3% overall incidence of the primary endpoint event compared to 12% in other trials.”

The physician-initiated, prospective, multi-centre, randomised REDUCE trial is designed to procure evidence for a different DAPT regimen and new-generation stent.

Conducted in 1,496 subjects at 36 hospitals in Europe and Asia, REDUCE measured primary clinical endpoint as a composite of all-cause mortality, all myocardial infarction, stent thrombosis, stroke, target vessel, revascularisation and moderate or severe bleeding within 360 days after randomisation.

REDUCE showed 8.3% overall incidence of the primary endpoint event compared to 12% in other trials.

The results were found to be consistent across all subgroups without any interaction that was statistically significant.

Clinical follow-ups carried out at three, six months and one year are scheduled to continue for two years post-randomisation.